Revenues increased 220% to $3.7 million, compared with $1.2 million for the fiscal year ended March 31, 2024 Expect to report revenue of at ...

New subsidiary, Cynaptec Pharmaceuticals, established to hold global rights to Conjugated Psilocin™ $6 million investment in Cynaptec Pharmaceuticals secured to advance research and early-stage ...